Vedolizumab treatment persistence and safety in a 2‐year data analysis of an extended access programme

類似資料

• Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn’s Disease or Ulcerative Colitis
  著者:: Vermeire, Séverine, 等
  出版事項: (2020)
• Long‐term safety of vedolizumab for inflammatory bowel disease
  著者:: Loftus, Edward V., 等
  出版事項: (2020)
• Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study
  著者:: Ooi, Choon Jin, 等
  出版事項: (2021)
• Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study
  著者:: Banerjee, Rupa, 等
  出版事項: (2021)
• Vedolizumab trough level monitoring in inflammatory bowel disease: a state-of-the-art overview
  著者:: Pouillon, Lieven, 等
  出版事項: (2019)